Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas sells US production site to APP

This article was originally published in Scrip

Executive Summary

Astellashas sold a US manufacturing facility in Grand Island, New York, toAPP Pharmaceuticals. The move forms part of a wider reduction in production facilities under Astellas's current mid-term business plan, which calls for cutting the number of these to around 10 worldwide by April 2011. The Japanese firm will continue to lease the facility from APP until next spring, when it will transfer the production of the atopic dermatitis product Protopic (topical tacrolimus) from there to its Toyama plant in Japan. APP, a US firm specialising in generic injectables, already has operations on Grand Island and will offer employment to most of the 90 or so employees at the former Astellas facility.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel